Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight

Positive

AI Analysis

Summary

DelveInsight projects the autoimmune uveitis market will grow at a 7% CAGR through 2036, driven by increased diagnosis of non-infectious uveitis and demand for novel steroid-sparing therapies.

Importance:2/10

Sentiment:

0.30

market analysisautoimmune uveitistherapeutic landscapesteroid-sparing therapiesimmunomodulatory treatments

Read the original article

Published by PR Newswire Biotech on September 2, 2026 2:31 PM

Read Original